Introduction
Introduction Statistics Contact Development Disclaimer Help
DTIC ADA579691: Evaluating the Efficacy of ERG Targeted Therapy In ...
by Defense Technical Information Center
Thumbnail
Download
Web page
The proposed research will examine the suitability of ERG
as a target for prostate cancer therapy by using novel
modular inducible transgenic mice. Prostate cancer is a
large health problem in the United States. Recent efforts
to classify distinct molecular subtypes of prostate
cancer have shown that 50% of prostate cancers possess a
chromosomal translocation involving the ERG oncogene. I
hypothesized that ERG can serve as an effective molecular
therapeutic target for prostate tumors. I planned to show
this with novel autochthonous prostate tumor mouse
models. During this second year of support we have not
been able to been able to adhere to the timeline of our
Statement of Work - Task#2 - Determine if ERG cooperates
with AKT1 for prostate tumorigenesis (months 14-34). We
were previously successful at completing the tasks for
Task#1 - Generate and characterize an inducible ERG
prostate specific mouse model (months 1-17), but our
characterization of ERG expression from our prostate
inducible mouse model did not demonstrate any detectable
prostate specific ERG expression at the protein level.
Data from another project using the ARR2PB-tTA line has
lead us to believe that the level of expression from the
ARR2PB-tTA line is low and perhaps insufficient for the
in vivo experiments described in our proposal. We are now
planning to pursue the Hoxb13-rtTA mouse line allows for
much more robust expression of tetO target genes in the
mouse prostate.
Date Published: 2018-09-10 15:31:54
Identifier: DTIC_ADA579691
Item Size: 16939173
Language: english
Media Type: texts
# Topics
DTIC Archive; ; JOHNS HOPKINS UNIV BA...
# Collections
dticarchive
additional_collections
# Uploaded by
@chris85
# Similar Items
View similar items
PHAROS
You are viewing proxied material from tilde.pink. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.